Loading
Latest filing published 11 Sept 2026 for Relmada Therapeutics, INC., €434k.
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Maged Shenouda has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Relmada Therapeutics, Inc., GridAI Technologies Corp. and Protea Biosciences Group, Inc. The record holds 47 filings, for trades running from 14 December 2015 to 10 September 2026.
Market trades split into 19 purchases (€2.1M) and 18 sales (€1.0M). Netting one side against the other leaves €1.1M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants and 8 option exercises. Since January 2026: 2 purchases and no sales on the market.
Half of the purchases are above €28k and half below. On 15 out of 15 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 60% of cases; the median change was +19.7%. These figures describe past trades and do not predict future prices.
The newest entry dates from 11 September 2026: an open-market purchase of €434k, in Relmada Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations